弓漿蟲病治療市場：依藥物類別、適應症、給藥途徑、通路及地區分類

預計到2026年，弓漿蟲病治療市場規模將達38.72億美元，2033年將達到56.324億美元。預計從2026年到2033年，該市場將以5.5%的複合年成長率成長。

弓形蟲病是由弓形蟲（Toxoplasma gondii）引起的感染疾病。目前推薦的弓形蟲病藥物主要針對速殖子階段的寄生蟲，並不能將其從組織中徹底清除。乙胺嘧啶被認為是最有效的抗弓形蟲藥物，也是標準治療方案的組成部分。乙胺嘧啶是一種葉酸拮抗劑，可引起劑量依賴性的骨髓抑制，但同時服用葉酸（亞葉酸鈣）可以減輕這種抑製作用。亞葉酸鈣可以保護骨髓免受乙胺嘧啶的毒性作用。如果患者對磺胺類藥物出現過敏反應，則可能需要加上其他藥物，例如磺胺嘧啶或克林黴素。其他用於治療弓形蟲病的藥物包括組合藥物磺胺甲噁唑（甲氧芐啶和磺胺甲噁唑）以及阿托伐醌、乙胺嘧啶和阿奇黴素。

市場動態

藥物用於治療活動性感染疾病。影響治療的因素包括疾病的嚴重程度、免疫系統狀態和感染部位。妊娠階段也是一個重要因素。例如，2022年11月3日，美國梅奧診所發表了報導，說明了乙胺嘧啶（達拉匹林），一種用於對抗微生物感染疾病的藥物。這種藥物會抑制人體對葉酸的利用。長期使用乙胺嘧啶的其他副作用包括骨髓抑制和肝毒性。亞葉酸鈣有助於矯正乙胺嘧啶對葉酸的影響。磺胺嘧啶是一種常與乙胺嘧啶合併使用的抗生素。其他藥物包括克林黴素（克立舒）和阿奇黴素（希舒美）。如果懷疑新生兒弓形蟲病，醫師會進行血液檢查。血液檢查結果呈陽性的嬰兒需要接受多項檢查，以確定疾病類型並後續觀察。

本研究的主要特點：

• 這項研究揭示了各個細分市場的潛在成長機會，並為該市場說明了一個有吸引力的投資提案矩陣。
• 此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及領先企業採取的競爭策略。
• 本研究根據以下參數介紹了全球弓形蟲病治療市場主要公司的概況：公司概況、產品系列、主要亮點、財務表現和策略。
• 本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品類型升級、市場擴張和行銷策略做出明智的決策。
• 這份「全球弓形蟲病治療市場」報告旨在為業界的各類相關人員提供參考，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
• 相關人員可以透過利用全球弓形蟲病治療市場分析中使用的各種策略矩陣來簡化決策過程。

目錄

第1章：研究目標與前提條件

• 分析目的
• 先決條件
• 簡稱

第2章 市場展望

• 報告說明
  • 市場定義和範圍
• 執行摘要
• Coherent Opportunity Map（COM）

第3章：市場動態、監管與趨勢分析

• 市場動態
  • 促進因素
  • 抑制因子
  • 市場機遇
• 影響分析
• 近期產品發布
• 流行病學
• 併購和合作
• 監管趨勢
• 主要進展
• PEST分析

第4章 全球弓漿蟲病治療藥物市場：依藥物類別分類，2021-2033年

• 乙胺嘧啶
• 螺旋黴素
• 亞葉酸鈣
• 磺胺嘧啶
• 葉酸
• 其他

第5章 全球弓漿蟲病治療市場：依適應症分類，2021-2033年

• 慢性弓漿蟲病
• 急性弓漿蟲病

第6章 全球弓漿蟲病治療藥物市場：依給藥途徑分類，2021-2033年

• 腸外
• 口服

第7章 全球弓漿蟲病治療市場：依通路分類，2021-2033年

• 醫院藥房
• 網路藥房
• 零售藥房

第8章 全球弓漿蟲病治療市場：依地區分類，2021-2033年

• 北美洲
  • 美國
  • 加拿大
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲國家
• 歐洲
  • 英國
  • 德國
  • 義大利
  • 法國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韓國
  • 其他亞太國家
• 中東
  • GCC
  • 以色列
  • 其他中東國家
• 非洲
  • 北非
  • 中非
  • 南非

第9章 競爭情勢

• Vyera Pharmaceuticals LLC
• Taj Accura Pharmaceuticals Ltd
• Mangalam Drugs and Organics Ltd
• Cerovene Healthcare PVT LTD
• Greenstone LLC
• Amneal Pharmaceuticals, Inc.
• Turing Pharmaceuticals
• F.Hoffmann-La Roche AG
• Teva Pharmaceutical Industries Ltd
• Baxter International Inc

第10章

• 調查方法
• 關於本公司

Toxoplasmosis Treatment Drugs Market is estimated to be valued at USD 3,872.0 Mn in 2026 and is expected to reach USD 5,632.4 Mn by 2033, growing at a compound annual growth rate (CAGR) of 5.5% from 2026 to 2033.

Toxoplasmosis is an infection caused by a parasite called Toxoplasma gondii. Currently recommended toxoplasmosis drugs target the tachyzoite stage of the parasite and do not remove the parasite from the tissues. Pyrimethamine is considered the most effective anti-toxoplasmosis drug, and it is a standard component of treatment. Pyrimethamine is a folic acid antagonist and can cause dose-dependent bone marrow suppression, which is alleviated by the concomitant administration of folic acid (leucovorin). Leucovorin protects the bone marrow from the toxic effects of pyrimethamine. If the patient experiences a hypersensitive reaction to sulfa medications, another medication, such as sulfadiazine or clindamycin, should be added. As an alternative, a fixed combination of trimethoprim with sulfamethoxazole and other drugs such as atovaquone and pyrimethamine and azithromycin are used for toxoplasmosis treatment.

Market Dynamics

Medicines are used to treat active infections. These factors include the severity of your illness, the state of your immune system, and the location of the infection. Another aspect is pregnancy's stage. For example, on November 3, 2022, a U.S.-based hospital, Mayo Clinics published an article explaining pyrimethamine (Daraprim), which fights against infections caused by microscopic organisms. It can block the body's use of folic acid. Other possible side effects of its long-term use include bone marrow suppression and liver toxicity. Leucovorin calcium helps correct the effect of pyrimethamine on folic acid. Sulfadiazine is an antibiotic often prescribed with pyrimethamine. Other medications include clindamycin (Cleocin), azithromycin (Zithromax), and others. To diagnose toxoplasmosis in a newborn baby, blood tests are prescribed if infection is suspected. A baby with a positive test result will undergo many tests to identify and monitor the disease.

Key features of the study:

• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global toxoplasmosis treatment drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Vyera Pharmaceuticals LLC, Taj Accura Pharmaceuticals Ltd, Mangalam Drugs and Organics Ltd, Cerovene Healthcare PVT LTD, Greenstone LLC, Amneal Pharmaceuticals, Inc., Turing Pharmaceuticals, F.Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd, and Baxter International Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global toxoplasmosis treatment drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global toxoplasmosis treatment drugs market

Detailed Segmentation:

• Global Toxoplasmosis Treatment Drugs Market, By Drug Class (Revenue, USD Mn, 2021 - 2033)
• Pyrimethamine
• Spiramycin
• Leucovorin
• Sulfadiazine
• Folic Acid
• Others
• Global Toxoplasmosis Treatment Drugs Market, By Indication (Revenue, USD Mn, 2021 - 2033)
• Chronic Toxoplasmosis Infection
• Acute Toxoplasmosis Infection
• Global Toxoplasmosis Treatment Drugs Market, By Route of administration (Revenue, USD Mn, 2021 - 2033)
• Parenteral
• Oral
• Global Toxoplasmosis Treatment Drugs Market, By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies
• Global Toxoplasmosis Treatment Drugs Market, By Region (Revenue, USD Mn, 2021 - 2033)
• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Europe
  • U.K.
  • Germany
  • France
  • Spain
  • Italy
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • North Africa
  • Central Africa
  • South Africa
• Company Profiles
• Vyera Pharmaceuticals LLC
• Taj Accura Pharmaceuticals Ltd
• Mangalam Drugs and Organics Ltd
• Cerovene Healthcare PVT LTD
• Greenstone LLC
• Amneal Pharmaceuticals, Inc.
• Turing Pharmaceuticals
• F.Hoffmann-La Roche AG
• Teva Pharmaceutical Industries Ltd
• Baxter International Inc

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Class
  • Market Snapshot, By Indication
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Recent Product Launches
• Epidemiology
• Merger, Acquisition, and Collaborations
• Regulatory Scenario
• Key Developments
• PEST Analysis

4. Global Toxoplasmosis Treatment Drugs Market, by Drug Class, 2021 - 2033, (US$ Million)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022-2033
  • Segment Trends
• Pyrimethamine
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)
• Spiramycin
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)
• Leucovorin
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)
• Sulfadiazine
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)
• Folic Acid
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)

5. Global Toxoplasmosis Treatment Drugs Market, By Indication, 2021 - 2033, (US$ Million)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022-2033
  • Segment Trends
• Chronic Toxoplasmosis Infection
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)
• Acute Toxoplasmosis Infection
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)

6. Global Toxoplasmosis Treatment Drugs Market, by Route of Administration, 2021 - 2033, (US$ Million)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022-2033
  • Segment Trends
• Parenteral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)

7. Global Toxoplasmosis Treatment Drugs Market, by Distribution Channel, 2021 - 2033, (US$ Million)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022-2033
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)

8. Global Toxoplasmosis Treatment Drugs Market, By Region, 2021 - 2033, (US$ Million)

• Introduction
  • Market Share Analysis, By Region, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, For Region, 2022-2033
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (US$ Million)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (US$ Million)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (US$ Million)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2021-2033, (US$ Million)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Vyera Pharmaceuticals LLC
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Taj Accura Pharmaceuticals Ltd
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Mangalam Drugs and Organics Ltd
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Cerovene Healthcare PVT LTD
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Greenstone LLC
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Amneal Pharmaceuticals, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Turing Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• F.Hoffmann-La Roche AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Teva Pharmaceutical Industries Ltd
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Baxter International Inc
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies

10. Section

• Research Methodology
• About Us